Renaissance Technologies
CMMB

Renaissance Technologies’s Chemomab Therapeutics CMMB Stock Holding History

Renaissance Technologies’s Portfolio CMMB Stock Details CMMB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-6,990
Closed -$134K – 4260
2022
Q1 		$134K Buy
+6,990
New +$138K ﹤0.01% 3743
2021
Q2 		– Sell
-1,756
Closed -$202K – 3493
2021
Q1 		$202K Buy
1,756
+420
+31% +$83.6K ﹤0.01% 3146
2020
Q4 		$148K Buy
+1,336
New +$129K ﹤0.01% 3203

Other funds holding CMMB

CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
MIH
Meitav Investment House Bene-Beraq, Israel $9.12B AUM 42.07% 1-Year Est. Return
Envestnet Asset Management
Envestnet Asset Management Chicago, Illinois $374B AUM 17.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ASN
Advisory Services Network Atlanta, Georgia $7.52B AUM 29.01% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Renaissance Technologies's CMMB Position: Q2 2022 in Review

Renaissance Technologies sold out of Chemomab Therapeutics (CMMB) in Q2 2022, closing a stake of 6,990 shares — an estimated $134K sold.

Renaissance Technologies first reported a position in CMMB in Q4 2020 and held it in 3 quarters. The position peaked at $202K in Q1 2021. 15 funds tracked by Wall St. Rank hold CMMB as of Q2 2022.

  • Renaissance Technologies reported no remaining Chemomab Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Renaissance Technologies sold 6,990 Chemomab Therapeutics shares in Q2 2022, an estimated $134K.
  • Renaissance Technologies first reported a position in Chemomab Therapeutics in Q4 2020 and held it in 3 quarters.
  • Renaissance Technologies's Chemomab Therapeutics position peaked at $202K in Q1 2021.
  • 15 funds tracked by Wall St. Rank held Chemomab Therapeutics as of Q2 2022.

Based on Renaissance Technologies's 13F filing for Q2 2022, filed 12 Aug 2022.